Skip to main content
main-content

01.12.2015 | Study protocol | Ausgabe 1/2015 Open Access

BMC Endocrine Disorders 1/2015

Design and rationale of the IN CONTROL trial: the effects of real-time continuous glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus and impaired awareness of hypoglycemia

Zeitschrift:
BMC Endocrine Disorders > Ausgabe 1/2015
Autoren:
Cornelis A.J. van Beers, Susanne J. Kleijer, Erik H. Serné, Petronella H. Geelhoed-Duijvestijn, Frank J. Snoek, Mark H.H. Kramer, Michaela Diamant
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12902-015-0040-3) contains supplementary material, which is available to authorized users.

Competing interests

This is an investigator initiated trial. Medtronic provided the study devices and accessories. Eli Lilly and Sanofi Aventis provided financial support, but had no role in writing or publication of this manuscript. All authors declare that they have no competing interests.

Authors’ contributions

MD and SK conceived and designed the design. CAJB, ES, PHG, FJS, MHHK participated in the study design. CAJB mainly drafted the initial manuscript and SK, ES, PHG, FJS and MHHK provided advice on the manuscript. All authors read and approved the manuscript.

Abstract

Background

Hypoglycemia is the main side effect of intensified insulin therapy in type 1 diabetes and recognized as a limitation in achieving glycemic targets. Patients with impaired awareness of hypoglycemia have a threefold to sixfold increased risk of severe hypoglycemia. Real-time continuous glucose monitoring may help patients with type 1 diabetes to achieve better glycemic control with less hypoglycemic episodes. Accordingly, one may hypothesize that particularly type 1 diabetes mellitus patients with impaired awareness of hypoglycemia will profit most from this technology with improvements in their quality of life. However, this has not yet been established. This trial aims to study the effect of real-time continuous glucose monitoring on glycemia and quality of life specifically in type 1 diabetes mellitus patients with established impaired awareness of hypoglycemia.

Methods/design

This is a two-center, randomized, cross-over trial with a 12-week wash-out period in between intervention periods. A total of 52 type 1 diabetes mellitus patients with impaired awareness of hypoglycemia according to Gold et al. criteria will be randomized to receive real-time continuous glucose monitoring or blinded continuous glucose monitoring for 16 weeks. After a wash-out period, patients will cross over to the other intervention. The primary outcome measure is time spent in euglycemia. Secondary outcomes include (diabetes-specific) markers of quality of life and other glycemic variables.

Discussion

It remains unclear whether patients with type 1 diabetes and impaired awareness of hypoglycemia benefit from real-time continuous glucose monitoring in real-life. This study will provide insight into the potential benefits of real-time continuous glucose monitoring in this patient population.

Trial registration

Clinicaltrials.gov: NCT01787903.
Zusatzmaterial
Additional file 1: Table S1. Overview of visits, telephone consultations and outcome assessments. (XLS 34 kb)
12902_2015_40_MOESM1_ESM.xls
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Endocrine Disorders 1/2015 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Herausgeber:
Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Herausgeber:
Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise